{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.3698","value":"21.943"},{"groupId":"OG001","spread":"0.7289","value":"0.596"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.","id":"OG000","title":"ACZ885"},{"description":"Placebo subcutaneous injection every 8 weeks.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Intention to treat (ITT) population.","reportingStatus":"POSTED","timeFrame":"32 weeks after study start","title":"Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part II.","type":"SECONDARY","unitOfMeasure":"pg/mL"}